
XenTech
Predictive PDX, Efficient Therapeutics
www.xentech.eu

Who are we ?

Originally a spin-off of the Institut Curie, at XenTech, we are dedicated to advance the development of new anti-cancer therapies by offering access to the most relevant science-driven PDX models and *in vitro*, *in vivo* preclinical services.

We aim at developing successfully your oncotherapeutics, accessing an innovative translational platform with clinically relevant tumor models to address tomorrow's needs in preclinical oncology research.

What we do?

We pioneered the Patient-Derived tumor Xenograft models (PDX) approach and were one of the first CROs to develop oncotherapeutic candidates combining these innovative models with early preclinical services.
Our expertise and technology were forged on one of the world's reference and most published PDX collection.

Predictive PDX to optimize your oncology therapeutics

- Wide and unique collection of clinically-relevant PDX models with confirmed clinical correlations
- World-class reference breast, prostate and pediatric liver cancer PDX panels
- From discovery to clinical success: translational *in vitro* and *in vivo* studies



Start your efficacy program with *in vitro* PDX-derived cells

With more than 40 PDX-derived cell cultures representing various solid tumor indications, you can rapidly start your oncotherapeutics efficacy in vitro studies. The PDX-DC testing allows to pre-validate the model to continue your in vivo assays with the parental PDX models.

Using our range of PDX-DC models, you can:

- Run *in vitro* assays directly at your laboratory using dedicated license or outsource your in vitro testing at XenTech.
- Benefit from low-passage cell cultures keeping parental PDX tumor heterogeneity, culture conditions optimized for each model, with no selective pressure applied.
- Access fully characterized cells: RNAseq and WES data for controlled molecular matching with the parental PDX models.

First-in-class PDX models to derisk your therapeutics against cancer

Breast

At XenTech, the patient-derived tumorgrafts consist of a wide bank of clinically-relevant PDX models with correlation to clinical outcomes. The models reflect disease characteristics that closely mirror those of patients. The breast cancer PDX tumor models have been developed to allow in vivo screening and include up to 50 breast predictive PDX models. Those models have been extensively characterized regarding their molecular features (WES and RNAseq, aCGH, ...) as well as their response to standards of care (A/C, Capcitabline, Docetaxel, Trastuzumab, Lapatinib, PARPi, etc.).

- Widely published clinically relevant PDX models
- Triple negative breast cancer models HR+ and HER2+
- Extensive PARP and DDR inhibitors information
- Deep characterization with WES and RNAseq
- Ready-to-start studies with models kept warm

Prostate

Developing PDX from prostate cancer (PC) is known to be more challenging than for other indications. The lack of relevant models is a major limitation in prostate cancer research. In particular, the development of models from castration-resistant tumors is a requirement to explore new treatments. To help develop such therapies, XenTech offers a growing panel of castration-resistant prostate cancer (CRPC) PDX as well as AR-dependent PDX models.

- Highly clinically relevant prostate PDX
- Advanced genomic
- WES and RNAseq data
- AR-dependant PC & CRPC models
- Neuroendocrine models
- Castration and AR antagonist/inhibitor responses

Lung

Lung cancer is one of the most common types of cancer in the world. With this prominence, reliable preclinical lung models are essential for new therapeutic development. XenTech lung cancer PDX models (NSCLC and SCLC) are predictive and give way to translational approaches to evaluate efficacy at early stage of development. We offer a wide collection of characterized models (40+ PDX models).

Pediatric

Supported by the European consortium 'Innovative Medicines Initiative' (IMI2), XenTech actively participates in the ITCC-P4 (Innovative Therapies for Children with Cancer Paediatric Preclinical Proof-of-concept Platform) project aiming at establishing and characterizing a collection of 400 PDX models of the most common pediatric solid high-risk entities. At XenTech, we perform mouse trial assays using a panel of standard of care (SOC) and investigational drugs.

Predictive PDX, Efficient Therapeutics

Innovative models

- More than 200 PDX models
- Over 50 PDX-derived cellular models
- Pediatric PDX cancer models from solid tumors
- Specific PDX from patients with acquired resistance
- Syngeneic models & humanized mice

Services & Resources

- Drug • Drug efficacy & Mouse clinical trials
- *In vitro* screening
- Whole Exome Sequencing & RNAseq
- IHC protein expression
- Tissue sampling
- Pharmacological profiling (standards of care)

XenTech

bdteam@xentech.eu | +33 6 19 98 57 96

www.xentech.eu